---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-014760"
form_type: "8-K"
ticker: "MTVA"
cik: "0001638287"
company_name: "MetaVia Inc."
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:36:26.155109+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# NeuroBo Q3 net loss $5.7M, cash $21.7M; positive Phase 1 SAD data for obesity drug DA-1726

## Summary
- Net loss of $5.7M (EPS -$0.55) for Q3 2024 vs. $3.8M net loss ($0.75 per share) in Q3 2023.
- Cash at Sept 30, 2024: $21.7M; expected to fund operations into Q3 2025.
- Positive top-line data from SAD Part 1 of Phase 1 trial for DA-1726: safe, tolerable, dose-linear PK; additional cohorts exploring MTD.
- DA-1241 Phase 2a MASH trial: top-line data expected in December 2024.
- Entered joint research agreement with Dong-A ST and ImmunoForge for once-monthly formulation of DA-1726.

## SEC filing metadata
- accession: 0001558370-24-014760
- form_type: 8-K
- ticker: MTVA
- cik: 0001638287
- company_name: MetaVia Inc.
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1638287/000155837024014760/0001558370-24-014760-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1638287/000155837024014760/nrbo-20241107x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-014760
- JSON: https://secwatch.observer/filing/0001558370-24-014760.json
- Plain text: https://secwatch.observer/filing/0001558370-24-014760.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.